Chitosan/Alginate-Based Nanoparticles for Antibacterial Agents Delivery
DOI: https://doi.org/10.2147/ijn.s469572
IF: 7.033
2024-05-30
International Journal of Nanomedicine
Abstract:Nasrul Wathoni, 1, &ast Yedi Herdiana, 1, &ast Cecep Suhandi, 1, &ast Ahmed Fouad Abdelwahab Mohammed, 2, &ast Ali El-Rayyes, 3, &ast Angga Cipta Narsa 4, &ast 1 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia; 2 Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt; 3 Department of Chemistry, College of Science, Northern Border University, Arar, Saudi Arabia; 4 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Mulawarman University, Samarinda, 71157, Indonesia &astThese authors contributed equally to this work Correspondence: Nasrul Wathoni, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia, Tel +62-22-842-888-888, Email Nanoparticle systems integrating alginate and chitosan emerge as a promising avenue to tackle challenges in leveraging the potency of pharmacological active agents. Owing to their intrinsic properties as polysaccharides, alginate and chitosan, exhibit remarkable biocompatibility, rendering them conducive to bodily integration. By downsizing drug particles to the nano-scale, the system enhances drug solubility in aqueous environments by augmenting surface area. Additionally, the system orchestrates extended drug release kinetics, aligning well with the exigencies of chronic drug release requisite for antibacterial therapeutics. A thorough scrutiny of existing literature underscores a wealth of evidence supporting the utilization of the alginate-chitosan nanoparticle system for antibacterial agent delivery. Literature reviews present abundant evidence of the utilization of nanoparticle systems based on a combination of alginate and chitosan for antibacterial agent delivery. Various experiments demonstrate enhanced antibacterial efficacy, including an increase in the inhibitory zone diameter, improvement in the minimum inhibitory concentration, and an enhancement in the bacterial reduction rate. This enhancement in efficacy occurs due to mechanisms involving increased solubility resulting from particle size reduction, prolonged release effects, and enhanced selectivity towards bacterial cell walls, stemming from ionic interactions between positively charged particles and teichoic acid on bacterial cell walls. However, clinical studies remain limited, and there are currently no marketed antibacterial drugs utilizing this system. Hence, expediting clinical efficacy validation is crucial to maximize its benefits promptly. Keywords: alginate, chitosan, polymeric nanoparticle, antibacterial agents, drug delivery, controlled release, nano-delivery systems One of the primary challenges encountered by drug molecules, particularly newly developed ones, is their limited solubility. Studies indicate that nearly 40% of newly discovered chemical entities exhibit low solubility in water. 1,2 This low solubility adversely affects their bioavailability, resulting in restricted absorption by the body. 3 Consequently, drugs often need to be administered in high doses to achieve the desired therapeutic effect. 4 A concrete example of this problem can be found in drugs classified as Biopharmaceutics Classification System (BCS) class II and IV. 5 Class II drugs exhibit low solubility but high permeability, whereas class IV drugs display low solubility and permeability. 6 Such circumstances present a significant challenge in the development of effective and efficient drug formulations. Among the many drug candidates with solubility issues in water, antibacterial agents are the most affected. For instance, the use of marketed antibiotics, such as amoxicillin, faces challenges due to its low solubility in water. This limits the oral use of amoxicillin, as the reconstitution process with water is restricted to 150 mg/mL. With the need for higher doses, clinicians generally prefer intravenous injection, which poses issues regarding patient comfort and increases healthcare facility costs. 7 In addition, curcumin, a prominent example characterized by low water solubility, measuring a mere 11 ng/mL. 8 This inherent limitation translates to poor bioavailability of curcumin, whether administered orally or topically. 9 Furthermore, curcumin is prone to rapid degradation during distribution processes. 10,11 Consequently, despite the minimal amount of the drug that reaches the bloodstream, its swift elimination significantly limits its effectiveness in treating diseases. The insufficient effectiveness of a -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology